Intellia Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Intellia Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2024.
  • Intellia Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$139M, a 5.07% decline year-over-year.
  • Intellia Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$524M, a 13.9% decline year-over-year.
  • Intellia Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$515M, a 12.5% decline from 2022.
  • Intellia Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$458M, a 71.1% decline from 2021.
  • Intellia Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$268M, a 96.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$524M -$139M -$6.71M -5.07% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$517M -$114M -$2.05M -1.83% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$515M -$140M -$29.8M -27.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 -$485M -$131M -$25.6M -24.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$460M -$132M -$34M -34.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$426M -$112M +$32.3M +22.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$458M -$110M -$29.7M -36.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 -$428M -$106M -$33.5M -46.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$395M -$98.3M -$29.3M -42.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$366M -$144M -$97.8M -211% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$268M -$80.4M -$38M -89.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 -$230M -$72M -$43.9M -156% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$186M -$69M -$36M -109% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$150M -$46.4M -$13.4M -40.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$137M -$42.4M -$12.6M -42.4% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-26
Q3 2020 -$124M -$28.1M -$2.77M -11% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$121M -$33M -$5.57M -20.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$116M -$33M -$9.24M -38.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$106M -$29.8M -$9.03M -43.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-26
Q3 2019 -$97.3M -$25.3M -$1.23M -5.1% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-26
Q2 2019 -$96.1M -$27.5M -$3.87M -16.4% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-26
Q1 2019 -$92.2M -$23.8M -$1.38M -6.15% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-26
Q4 2018 -$90.9M -$20.7M +$3.97M +16.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$94.8M -$24.1M -$8.22M -51.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$86.6M -$23.6M -$7.58M -47.3% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$79M -$22.4M -$9.48M -73.2% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$69.6M -$24.7M -$13.9M -128% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 -$55.7M -$15.9M -$8.18M -106% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-27
Q2 2017 -$47.5M -$16M -$9.07M -131% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-27
Q1 2017 -$38.4M -$12.9M -$6.25M -93.4% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-27
Q4 2016 -$32.2M -$10.8M -$5.33M -97.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-14
Q3 2016 -$26.8M -$7.7M -$4.4M -133% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-14
Q2 2016 -$22.4M -$6.95M -$3.52M -103% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-14
Q1 2016 -$18.9M -$6.69M -$5.5M -460% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-14
Q4 2015 -$13.4M -$5.49M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-14
Q3 2015 -$3.3M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-14
Q2 2015 -$3.42M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-14
Q1 2015 -$1.2M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.